Monitor for trial initiation and any early safety/efficacy data from the TPST-4003 study. The in vivo CAR-T platform represents a novel approach, but clinical validation is years away. Watch for potential financing needs given the small market cap and early-stage pipeline.
Price Chart
Executive Summary
Tempest Therapeutics announced its next-generation in vivo CAR-T platform and plans to advance lead candidate TPST-4003 into a first-in-human clinical trial for myasthenia gravis and multiple sclerosis, with first dosing expected in Q4 2026. This represents a significant pipeline catalyst for the pre-revenue clinical-stage biotech, though the trial is small (10 patients) and early-stage.
Key Facts
- Announced next-generation in vivo CAR-T platform
- Lead candidate TPST-4003 to enter first-in-human clinical trial for myasthenia gravis and multiple sclerosis
- Trial expected to enroll approximately 10 patients
- First patient dosing anticipated in Q4 2026
- Company is a clinical-stage biotechnology with no approved products or revenue
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech with $16M market cap
Risk Factors
- Early-stage clinical trial with no prior human data for TPST-4003
- Small sample size (10 patients) limits statistical power
- Significant cash burn expected with no near-term revenue
- Competitive landscape in CAR-T and autoimmune therapies is crowded
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5100 (+0.04%) |
Oct 20, 2026 6d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5100 (−3.45%) |
Oct 20, 2026 6d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5100 (−3.45%) |
Oct 19, 2026 7d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5100 (−11.49%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5100 (+37.13%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5100 (+38.67%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5100 (−47.31%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5100 (−43.02%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5100 (−43.02%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5100 (+37.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers